Abstract
PDE5Is are an effective treatment for ED in SCI individuals. A real-life cohort study was performed to evaluate the adherence to PDE5Is as well as the dropout rate, almost 10 years after the initiation of treatment.
97 SCI patients suffering from ED that were treated with PDE5Is were evaluated in 2015. Concomitant cardiovascular diseases, hormonal and psychiatric disorders were excluded. Efficacy was evaluated with IIEF5 and SEP2&3 questions. We re-evaluate our data now in order to assess the adherence to PDE5Is, almost 10 years after.
10 years after we collected data from 81 patients out of the original 87 responders.
From the sildenafil group, 18 out of 31 responders are still on, 6 on daily us tadalafil, 1 on intra-cavernosal injections (ICI), 1 died, 2 were lost in follow up, 2 are off treatment due to lack of sexual partner and 1 stopped the medication due to other comorbidities.
From the vardenafil group 5/13 still are on, 2 on sildenafil, 2 daily tadalafil, 1 on ICI, 1 without partner and 2 stopped due to comorbidities..
From the avanafil group, 3/7 are still on, 1 on sildenafil and 2 on daily tadalafil.
From the on demand tadalafil group, 7/22 are still on, 5 on daily tadalafil, 2 on sildenafil, 2 were lost in follow up, 1 died, 1 on ICI, 2 without partner and 2 stopped due to other comorbidities.
From daily tadalafil group, 9 are still on, 1 died, 1 on ICI, 2 on sildenafil, 1 underwent penile prosthesis implantation and 1 stopped the medication due to other comorbidities..
After almost 10 years of follow up, the majority of our SCI patients remained on PDE5 inhibitors, either the one prescribed initially or a different one. The medication dropout rate, in our cohort, is approximately 20%, while other comorbidities and lack of sexual partner were the major reasons for withdrawal.
None.
